title: The effect of somatostatin analogue on chiasmal dysfunction from pituitary macroadenomas.
abstract: The long-acting somatostatin analogue SMS 201-995 has been shown to be efficient in the treatment of somatotropic and thyrotropic adenomas. In some cases, it can suppress adenoma secretion and lead to tumor shrinkage. Pituitary macroadenomas are often associated with a vision-threatening chiasmal syndrome. In this series, SMS 201-995 was administered subcutaneously to eight patients with pituitary macroadenomas of various types responsible for severe long-lasting visual defects. An obvious improvement of both visual fields and acuity occurred in six patients, in two of these during the first 4 to 6 hours of treatment; in two patients, gonadotropic adenomas were unresponsive. Maximal improvement (normalization of visual fields in three cases) occurred within 6 to 45 days and was sustained during the 1- to 12-month follow-up period. This effect seems independent of the type of adenoma since the adenomas secreting growth hormone (GH) and thyroid-stimulating hormone and silent corticotropic-secreting adenomas responded as well as did two of the non-functioning adenomas. In one acromegalic patient visual improvement was obtained while the abnormal GH secretion remained unaltered. In all cases but one, no tumor shrinkage could be demonstrated. These data demonstrate that SMS 201-995 can rapidly improve the chiasmal syndrome due to pituitary macroadenoma, and suggest that this effect might be independent of a reduction in tumor volume.
authors: Department of Internal Medicine, Hôpital Lariboisière, Paris, France.
authors: A
authors: A
authors: Warnet
authors: J
authors: J
authors: Timsit
authors: P
authors: P
authors: Chanson
authors: P J
authors: PJ
authors: Guillausseau
authors: F
authors: F
authors: Zamfirescu
authors: A G
authors: AG
authors: Harris
authors: P
authors: P
authors: Derome
authors: J
authors: J
authors: Cophignon
authors: J
authors: J
authors: Lubetzki
mesh_terms: D000236:Adenoma / Q000188:drug therapy* / Q000503:physiopathology; D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000494:pharmacology / Q000627:therapeutic use*; D009897:Optic Chiasm / Q000503:physiopathology; D009901:Optic Nerve Diseases / Q000188:drug therapy / Q000503:physiopathology; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D014792:Visual Acuity; D014794:Visual Fields
chemical_list: D015282:Octreotide